Azenta’s Share Price Advances 1.36 % Amid Moderate Market Activity
Azenta Inc. (NASDAQ: AZTA) closed the trading day on Monday, 26 November 2026, at USD 36.54, representing a 1.36 % increase over the previous close. At 12:57 PM Central European Time, the company’s shares were actively traded on major exchanges, with a volume of approximately USD 17.5 million during the preceding 24 hours.
With a market capitalization of roughly USD 1.6 billion and an outstanding supply of 43.8 million shares, Azenta continues to demonstrate steady growth. Since the close of the previous month, the stock has risen by 6.73 %. Its 200‑day simple moving average—an indicator often used to gauge medium‑term trend—stands at USD 28.34, well below the current trading level, suggesting a bullish stance among technical analysts.
Azenta’s highest point in the last 52 weeks was USD 46.41, reached on 10 June 2026, while the low for the same period was USD 15.93, recorded on 18 May 2026. The present price places the share near the upper third of its yearly range, indicating that investors are placing confidence in the company’s ongoing initiatives in cold‑chain management and genomic services.
Recent Market Context
In the past 24 hours, several peer companies in the life‑sciences and automotive technology sectors exhibited varied performance:
| Company | Symbol | 24‑hour change | Current price | Market cap | P/E ratio |
|---|---|---|---|---|---|
| Expro | XPRO | +8.11 % | USD 16.93 | USD 1.9 bn | 92.4 |
| Establishment Labs | ESTA | +0.44 % | USD 63.8 | USD 1.9 bn | – |
| Biolife | BJX1.F | +3.51 % | USD 38.61 | USD 1.9 bn | 37.66 |
| Visteon | VC | –6.52 % | USD 76.37 | USD 1.9 bn | 12.96 |
| Astrana Health | ASTH | –1.47 % | USD 37.45 | USD 1.9 bn | 45.33 |
Azenta’s modest gain contrasts with the more volatile movements of its peers, particularly Expro’s significant rise and Visteon’s decline. The stability of Azenta’s price may reflect the company’s diversified client base across pharmaceuticals, biotech, and academic research, as well as its ongoing investment in next‑generation cold‑chain and genomic technologies.
Company Overview
Azenta Inc. operates at the intersection of life sciences and logistics, providing integrated cold‑chain sample management solutions and genomic services. Its offerings span drug development, clinical research, and advanced cell therapies, catering to a global clientele that includes pharmaceutical manufacturers, biotechnology firms, academic institutions, and healthcare providers. The company’s strategic focus on innovation and cutting‑edge technology aims to streamline sample handling, reduce variability, and accelerate research timelines.
Investors interested in Azenta can obtain more detailed information on its services, initiatives, and corporate governance at the company’s website, www.azenta.com . Shares are listed on the Nasdaq exchange, offering liquidity and transparency for both institutional and retail investors.